KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Assets Average (2021 - 2025)

AbCellera Biologics (ABCL) has disclosed Assets Average for 5 consecutive years, with $1.4 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Assets Average fell 1.68% year-over-year to $1.4 billion, compared with a TTM value of $1.4 billion through Sep 2025, down 1.68%, and an annual FY2024 reading of $1.4 billion, down 5.95% over the prior year.
  • Assets Average was $1.4 billion for Q3 2025 at AbCellera Biologics, roughly flat from $1.4 billion in the prior quarter.
  • Across five years, Assets Average topped out at $1.6 billion in Q2 2022 and bottomed at $1.1 billion in Q1 2021.
  • Average Assets Average over 5 years is $1.4 billion, with a median of $1.4 billion recorded in 2024.
  • The sharpest move saw Assets Average skyrocketed 39.72% in 2022, then fell 8.35% in 2025.
  • Year by year, Assets Average stood at $1.2 billion in 2021, then grew by 24.16% to $1.5 billion in 2022, then dropped by 3.01% to $1.5 billion in 2023, then decreased by 8.23% to $1.4 billion in 2024, then grew by 0.17% to $1.4 billion in 2025.
  • Business Quant data shows Assets Average for ABCL at $1.4 billion in Q3 2025, $1.4 billion in Q2 2025, and $1.4 billion in Q1 2025.